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Quality of life (QOL) is increasingly seen as an important outcome in clinical care.
Etiology, diagnosis, and management of venous thrombosis have been studied
extensively, but only few studies have examined the impact of venous thrombosis on
quality of life.
The purpose of this study was to examine the impact of venous thrombosis on
quality of life in a well-defined population of patients with venous thrombosis, by
using both a generic and a disease-specific quality of life measure. A total of 45
patients from the thrombosis clinic of the University of Vermont in Burlington, VT,
returned a mailed questionnaire including the Short-Form 36 (SF-36) and a disease-
specific venous thrombosis-quality of life (VT-QOL) questionnaire about the problems
faced by patients with venous thrombosis.
The sample consisted of 13 men (28.9%) and 32 women (71.1%). The mean age
was 44.1 years, with a range from 21 to 80 years. Compared with population norms of
a general U.S. population that were adjusted for age and sex (N = 2463), venous
thrombosis patients scored significantly lower ( p < 0.05) on all subscales of the SF-
36. Patients with the postthrombotic syndrome (PTS) appeared to have more
impairment in their quality of life as measured by both the SF-36 and the disease-
specific questionnaire. All correlations between the SF-36 subscales and the
subscales of the VT-QOL were significant, most of them on a p < 0.01 level. Given
the impact of venous thrombosis and the postthrombotic syndrome on quality of life,
assessment of QOL should be included in future studies on the outcome of venous
thrombosis.
A 2004 Elsevier Ltd. All rights reserved.
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Whereas until about two decades ago, clinical and
laboratory measurements were the only indicators
of illness, recently, the patient’s own view on his
or her health has become increasingly important
in clinical care and research. Researchers have
developed a great number of self-report measure-
ments to assess patients’ own views on their
functioning and quality of life (QOL) [1]. Several
large clinical trials have shown that quality of life
as an outcome measure is responsive to important
clinical changes, and therefore it is increasingly
seen as an important outcome measure in diag-
nostic and treatment studies [2]. The World
Health Organization (WHO) definition of health
is: ‘A state of complete physical, mental and
social well-being and not merely the absence of
disease or infirmity’ [3]. Based on this definition,
quality of life in relation to health may be defined
as ‘the functional effect of an illness and its
consequent therapy upon a patient, as perceived
by the patient’. The domains that contribute to
this effect are physical, psychological, and social
functioning [3,4].
The annual incidence of diagnosed venous
thrombosis in western countries is 1 per 1000
persons [5,6]. In about 20% of patients, venous
thrombosis extends proximally, and of those
patients, 1--5% develop fatal pulmonary embolism
[7]. The postthrombotic syndrome (PTS) is a chronic
condition consisting of leg pain, edema, venous
ectasia, skin induration, and ulceration and is esti-
mated to occur in up to 50% of patients after an
episode of venous thrombosis [8,9].
Etiology, diagnosis, and management of venous
thrombosis have been studied extensively, but only
a few studies have examined the impact of venous
thrombosis on quality of life. Assessment of quality
of life in conditions like venous thrombosis may
provide important information on the burden of an
illness that is not normally captured by traditional
measures of morbidity [10].
A review on the subject of quality of life in
patients with chronic venous diseases identified a
total of 25 papers [11], of which 4 dealt with the
assessment of QOL in venous thrombosis [12--15].
These studies indicate that patients with venous
thrombosis report pain and impairment of their
physical functioning. They also found that patients
have low perceptions of their general health and
high health distress. Impairment of QOL appears to
be related to symptom severity and the presence of
the postthrombotic syndrome.
Instruments used to measure quality of life can
be classified into generic instruments and disease-specific instruments. Generic instruments allow
comparison across populations of patients with
different diseases, whereas disease-specific
instruments are sensitive to key dimensions of
quality of life that are impaired by specific dis-
eases. An advantage of disease-specific instru-
ments is that they increase acceptability of the
questionnaire to the patient by including only
relevant dimensions. A recommended research
approach for assessing quality of life is the com-
bination of generic and disease-specific instru-
ments in order to combine the advantages of
both methods [16--18]. Of the studies assessing
QOL in patients with venous thrombosis mentioned
above, only one study used both generic and
disease-specific instruments to measure quality
of life [13]. However, the authors failed to ob-
serve differences in the Short-Form 36 (SF-36)
scores between patients with and patients without
the postthrombotic syndrome.
The aim of this study was to examine the impact
of venous thrombosis on quality of life in a well-
defined population of patients with venous throm-
bosis by using both a generic and a newly developed
disease-specific measure. The aim of the present
study was to study the relationship between quality
of life, the presence of symptoms, and the presence
of the postthrombotic syndrome. An additional aim
was to test the disease-specific questionnaire for a
larger investigation.Materials and methods
Participants
Patients seen by one of the authors (M.C.) at the
thrombosis clinic of the University of Vermont
were considered for participation. Their charts
were reviewed for eligibility and the presence of
postthrombotic syndrome. Individuals under the
age of 18 years or who had comorbid disease were
excluded from the study. A total of 86 eligible
patients were selected to participate in the study.
Of the selected patients, 3 refused, 2 were de-
ceased, and 16 could not be reached. Following a
telephone call by a research nurse, 65 patients
(75.6%) gave their consent to participate. The
investigators contacted those 65 individuals by
phone and sent out the questionnaire and consent
forms by mail. Nonresponders received a reminder
questionnaire. The research protocol was ap-
proved by the local institutional review board of
the University of Vermont.
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Demographic and illness-related variables
The questionnaire included the following: age, sex,
marital status, employment status, number of epi-
sodes of thrombosis, location of thromboses, time
elapsed since last thrombosis, and a list of 11
symptoms that can be related to the postthrom-
botic syndrome. Patient charts were also reviewed
to classify the presence of the postthrombotic
syndrome as determined by a physician (M.C.).
Quality of life
As a generic quality of life instrument, the SF-36
was used [19]. The SF-36 is the most widely used
and evaluated generic instrument to measure
quality of life [20]. The SF-36 is a measure which
assesses functional, psychological, and social sta-
tus. It consists of 36 items spread over eight
dimensions, plus a single item giving information
on change in health over the past year. In
addition to the eight subscales, two summary
scores can be calculated: the Physical Component
Summary (PCS) and the Mental Component Sum-
mary (MCS). A major advantage of the SF-36 is
its extensive application in several disease con-
ditions and excellent psychometric characteris-
tics. The SF-36 has population norms available
against which the results of this study will be
compared [21].
As a disease-specific measure, a quality of life
questionnaire developed by the authors was used
(see Appendix A for sample items). The venous
thrombosis-quality of life (VT-QOL) questionnaire
was based on interviews held with thrombosis
patients and previous QOL research in venous
thrombosis [14,22,23]. The final instrument con-
sisted of questions assessing quality of life in the
dimensions physical functioning (7 items, a = 0.96),
social functioning (6 items, a = 0.94), general men-
tal health (6 items, a = 0.94), and thrombosis
repercussions (6 items, a = 0.88). We chose this
approach because according to the existing liter-
ature about QOL measurement in patients with
venous thrombosis, to accurately measure quality
of life, it is imperative to focus on physical,
emotional, and social functioning [24]. All items
were rated on a five-point Likert scale. It is
possible to calculate subscores on all subscales
with a range of 0--100 where 0 indicates worst
possible quality of life and 100 indicates best
possible quality of life. This is in line with the
scoring of the SF-36. Additional questions were
asked about the perceived severity of thrombosis,
overall restriction in daily activities, and per-
ceived pain.Statistical methods
All data were entered and analyzed using SPSS
11.0. Means were calculated for all SF-36 sub-
scales and compared to U.S. population norms
adjusted for age and sex, by means of t-tests.
Patients were grouped in three different ways:
patients with and without PTS, patients with and
without a recent event ( < 2 years ago), and
patients with one, two, or multiple events of
venous thrombosis. To compare scores between
groups, analysis of covariance (ANCOVA) was used
and analyses were adjusted for age and sex.
Simple univariate correlations were used to detect
relationships between subscales of the SF-36 and
the thrombosis-specific questionnaire. For all sta-
tistical tests, a p-value of 0.05 or less was con-
sidered significant.Results
Sample characteristics
A total of 45 out of 65 patients (69%) returned the
questionnaire. The sample consisted of 13 men
(28.9%) and 32 women (71.1%). The mean age was
44.1 years, with a range from 21 to 80 years. A
total of 13 subjects were unemployed (28.9%), of
whom 6 were unemployed due to disability
(13.3%). Nonresponders were more likely to be
male and were slightly younger than responders.
No differences were seen between the two groups
regarding the type of thrombosis the patients had
experienced.
In the participant group, the number of patients
with a recent thrombotic event, i.e., after 2000,
was slightly lower than in the nonresponders.
Respondents experienced between one and eight
thrombotic events, with a median of two episodes.
All 45 respondents experienced their most recent
thrombotic event between 1997 and 2002, with a
median elapsed time of 2 years; 38% had their most
recent thrombotic event after 2000.
From chart review, it was concluded that 20
subjects (44%) had no long-term physical effects
from their venous thrombosis and 25 (56%) had
mild or severe postthrombotic syndrome. There
were no significant differences in the presence of
the postthrombotic syndrome with respect to age,
sex, number of venous thromboses, and time
elapsed since the last episode. Patients with PTS
as diagnosed by a physician had a significantly
higher number of self-reported symptoms com-
pared to patients without PTS (3.4 vs. 1.4,
p< 0.01).
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Short-Form 36
Because our sample was composed of a higher
proportion of women and was older than the group
used for the general U.S. population norms
(N = 2463) [21], the U.S. population norms were
adjusted by weighting the norms with the age and
sex distribution in our sample. The venous throm-
bosis patients scored significantly lower on all sub-
scales of the SF-36 (see Fig. 1). The scores on the
Mental Health subscale are significantly lower at
the p < 0.05 level, and all others at the p< 0.01
level.
Table 1 lists the means of the SF-36 subscales
and summary scores for the three different group-
ings, namely, patients with a recent event and
those with an event longer ago, patients with
one, two, or multiple events, and patients with
and without PTS. To determine significant differ-
ences between the groups, analyses of covariance
were performed for the two summary scores. All
analyses were adjusted for age and sex.
The presence of PTS was associated with lower
SF-36 summary scores, indicating a worse quality of
life for patients with PTS. However, only the dif-
ference in mean scores on the Physical Component
Summary reached statistical significance [PCS: F(1,
39) = 4.42, p< 0.05, MCS: F(1, 39) = 1.35, p = 0.25].
There is no significant relationship in quality of
life scores between patients with a recent eventFig. 1 Mean scores of venous thrombosis patients onand those without a recent event, when adjusted
for PTS, although the Physical Component Summary
is slightly lower for patients without a recent event
and the Mental Component Summary is somewhat
higher for this group [PCS: F(4, 38) = 1.29, p = 0.29,
MCS: F(4, 38) = 1.14, p = 0.35].
The number of thrombotic events the patients
had experienced was divided into three groups
(one, two, or more than two events). A negative
trend was observed between number of thrombotic
events and Physical Component Summary. These
mean scores were not found to be significantly
different when adjusted for PTS [F(5, 37) = 0.863,
p = 0.52].
Venous thrombosis-quality of life questionnaire
Mean scores, standard deviations, and Cronbach’s
alpha’s on the disease-specific questionnaire
(N = 45) are shown in Table 2, along with corre-
lations between the subscales of this disease-
specific measure and the subscales of the SF-
36. Cronbach’s alpha’s for all subscales are high
(0.87--0.96), indicating a good internal consisten-
cy of the subscales. There were strong correla-
tions of scores of the VT-QOL and SF-36 scores. In
addition, pain and restriction in daily activities
were significantly correlated with most subscales,
especially physical functioning, physical role lim-
itations, and bodily pain. Perceived severity did
not correlate significantly with any of the SF-36
subscales.the SF-36 compared to an U.S. population sample.
Table 1 Mean SF-36 subscale and summary scores, for patients with and without a recent event, patients with and
without the postthrombotic syndrome (PTS), and patients with one, two, or more events
U.S. Venous Time since last event Presence of PTS Number of thrombotic events
population
norms
(N = 2463)
thrombosis
patients
(N = 45)
0--1 year
(N = 17)
> 2 years
(N = 28)
PTS
(N = 25)
No PTS
(N = 20)
1
(N = 21)
2
(N = 15)
>3
(N = 9)
Physical
functioning
83.6 73.9 80.6 69.9 64.2 86.1 84.6 62.9 67.2
Physical role
limitations
80.3 64.4 58.8 67.9 58.0 72.5 78.6 55.0 47.2
Bodily pain 74.0 64.0 61.6 65.4 56.0 74.0 75.2 54.7 53.1
General health
perceptions
71.2 58.3 59.6 57.5 55.0 62.4 60.9 58.2 52.1
Vitality 59.9 47.4 44.4 49.3 43.5 52.0 52.1 40.4 47.2
Social
functioning
82.8 72.2 69.1 74.1 67.0 78.8 77.4 66.7 69.4
Emotional role
limitations
80.8 67.4 56.9 73.8 58.7 78.3 76.2 55.6 66.7
Mental health 74.1 68.7 71.1 67.3 63.8 74.6 69.7 66.6 69.8
Physical health
component
50.0 44.2 45.2 43.6 41.0 48.1 49.1 40.1 39.1
Mental health
component
50.0 45.8 44.03 46.9 43.8 48.2 46.4 43.8 47.5
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QOL between the groupings (patients with and
without PTS, patients with and without a recent
event, and patients with one, two, or multiple
events), analyses of covariance were performedTable 2 Mean scores, standard deviations and Cronbach’s
questionnaire and correlations with SF-36 subscales for the
Subscales Mean Cronbach’s SF-36 subscales
VT-QOL
(range)
(S.D.) alpha PF PR BP
Physical
functioning
(0--100)
76.4
(28.5)
0.96 0.85** 0.66**
Social
functioning
(0--100)
83.6
(22.5)
0.92 0.77** 0.69**
General mental
health
(0--100)
75.0
(26.3)
0.94 0.70** 0.65**
Thrombosis
repercussions
(0--100)
72.7
(24.9)
0.87 0.51** 0.51**
Pain (1--6) 2.1
(1.3)
 0.38*  0.39* 
Perceived
severity
(1--5)
3.5
(1.3)
 0.05 0.12
Restriction
(1--3)
1.5
(0.5)
 0.62**  0.51** 
PF: Physical functioning; PR: Physical role limitations; BP: B
SF: Social functioning; ER: Emotional role limitations; MH:
*p < 0.05.
**p < 0.01.for all subscales. All analyses were adjusted for
age and sex. Mean scores are listed in Table 3.
Patients with PTS have significantly lower scores
on most VT-QOL than subjects without PTS, except
for general mental health, perceived severity, andalpha on the venous thrombosis-quality of life (VT-QOL)
venous thrombosis patient sample (N = 45)
GH VT SF ER MH
0.65** 0.40** 0.47** 0.46** 0.49** 0.38*
0.58** 0.32* 0.45** 0.50** 0.61** 0.50**
0.66** 0.68** 0.87** 0.78** 0.76** 0.84**
0.51** 0.44** 0.52** 0.54** 0.49** 0.61**
0.54**  0.27  0.11  0.24  0.17  0.17
0.24  0.03 0.06 0.03  0.07  0.12
0.46**  0.44*  0.32*  0.31*  0.42**  0.30
odily pain; GH: General health perceptions; VT: Vitality;
Mental health.
Table 3 Mean scores on the VT-QOL, for patients with and without a recent event, patients with and without the
postthrombotic syndrome (PTS), and patients with one, two, or more events
All patients
(N = 45)
Time since last event Presence of PTS Number of thrombotic events
0--1 year
(N = 17)
>2 years
(N = 28)
PTS
(N = 25)
No PTS
(N = 20)
1
(N = 21)
2
(N = 15)
>3
(N = 9)
Physical functioning 76.4 83.6 71.4 66.6 88.2 88.7 70.5 61.5
Social functioning 72.7 87.3 81.3 76.6 92.5 89.9 77.8 80.1
General mental health 83.6 75.2 74.8 67.2 84.4 81.3 69.2 70.8
Thrombosis
repercussions
75.0 75.0 71.3 63.7 83.5 83.8 66.7 58.3
Pain 2.1 1.7 2.3 1.6 2.5 1.8 2.0 2.7
Perceived severity 3.4 3.4 3.5 3.4 3.4 3.6 3.3 3.4
Restriction 1.5 1.4 1.5 1.6 1.3 1.3 1.5 1.7
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F(3, 39) = 3.43, p< 0.05; thrombosis repercussions:
F(3, 39) = 3.42, p < 0.05; social functioning: F(3,
39) = 2.98, p< 0.05; pain: F(3, 39) = 2.87, p< 0.05].
Patients with a recent event have significantly
lower scores on the physical functioning and pain
subscales of the VT-QOL, after adjusting for PTS
[physical functioning: F(4, 36) = 2.92, p < 0.05;
pain: F(4, 36) = 2.67, p< 0.05]. The other subscales
did not reach statistical difference.
A significant negative trend in scores was ob-
served between number of thrombotic events and
scores on the physical limitations [F(5, 37) = 2.83,
p < 0.05] and thrombosis repercussions subscales
[F(5, 37) = 2.86, p< 0.05]. This negative trend was
less obvious in the other subscales. A positive trend
in scores could be observed in pain and restriction
in daily activities (meaning that patients with more
thrombotic events experience more pain and are
more restricted in their daily life), but these trends
failed to reach statistical significance.Discussion
The results of this study indicate that the quality of
life of patients with venous thrombosis is impaired in
all domains. This impairment encompasses physical,
social, and psychological domains. Compared to a
general U.S. population sample, venous thrombosis
patients scored significantly lower on all subscales
of the SF-36 after adjusting the population norms for
the age and sex distribution in the sample.
The subjects in our study had their last throm-
botic event a median of 2 years ago, which indi-
cates that even after some years, quality of life of
patients with venous thrombosis is still impaired.
Given our results on both the SF-36 and thrombosis-
specific instrument, we can also conclude that
quality of life impairment is related to the pres-ence of self-reported symptoms and the presence
of the postthrombotic syndrome as reported by a
physician. Both findings are consistent with earlier
research [12--15]. From our results on the VT-QOL,
it can also be concluded that the quality of life of
venous thrombosis patients is more impaired after
multiple events.
A study by Kahn et al. [13] found that the
postthrombotic syndrome had a significant impact
on quality of life as measured by the disease-
specific measure VEINES-QOL, but no differences
were observed in the SF-36 scores. In our study,
however, we did detect significant differences
(p< 0.05) in the Physical Health Component score
between subjects with and subjects without the
postthrombotic syndrome. On our venous thrombo-
sis-quality of life questionnaire, those differences
were even more obvious and were found across
almost all dimensions. A reason for this could be
that most patients in our study had experienced
more than one thrombotic event, whereas in the
study by Kahn et al., patients with recurrent ve-
nous thrombosis were excluded. Accordingly, the
patients in our study might have had more severe
manifestations of PTS.
The disease-specific QOL measure that we used
in this study, the VT-QOL, was developed by our
group and has not been formally evaluated for
reliability and validity before, because the present
study was the first study to use and validate this
questionnaire. However, the good internal consis-
tency and high correlations with the SF-36 sub-
scales in this study give encouraging evidence for
its reliability and validity and its future use. Its
advantage to the SF-36 is the fact that it seems to
be more sensitive to the specific problems venous
thrombosis patients are facing, which can be con-
cluded from its ability to detect differences be-
tween patients with and patients without PTS.
Furthermore, unlike the SF-36, the instrument
was able to discriminate between patients with
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out a recent event.
When interpreting the results of this study,
some limitations should be taken into consider-
ation. We excluded patients with comorbid con-
ditions such as cancer to avoid confounding by
conditions that could affect quality of life in other
ways. This could limit the generalizability of our
study, but it is unlikely that it has affected the
major conclusions. Nonresponders were more like-
ly to have experienced a recent thrombotic event,
which might have influenced the results, although
time since last event was not found to be signifi-
cantly associated with QOL. Presence of PTS is best
determined for research purposes by a known scale
such as the CEAP classification [25]. In our study,
however, presence of PTS was determined by a
single clinician at different points in time prior to
the QOL assessment. The strong correlation be-
tween the classification of PTS by the clinician and
the self-reported symptoms at the time of QOL
determination suggests minimal impact of this
possible confounding factor. Use of a single ob-
server probably minimized the possibility of mis-
classification of PTS.
Given the observed impact of venous thrombosis
and the postthrombotic syndrome on quality ofN
a
Physical functioning
Finding a comfortable position to sleep 1
Standing for a long time 1
Social functioning
Social or leisure activities in which you are standing for
long periods (e.g., parties, weddings, shopping, etc.)
1
Social or leisure activities in which you are sitting for
long periods (e.g., going to the cinema or theatre)
1
General mental health
I feel on edge 1
I feel I am a burden to others 1
Thrombosis repercussions
I am frustrated about my thrombosis 1
I am worried about my future because of my thrombosis 1life, assessment of QOL should be included in
future studies on the outcomes of venous throm-
bosis, preferably with a disease-specific measure
like the VT-QOL. Venous thrombosis is a multicaus-
al disease that is caused by both genetic and
environmental factors [26]. Future studies might
also assess the impact of genetic testing for throm-
bophilia on quality of life. For clinical care, our
results indicate that health-care givers should be
sensitive about the impact of venous thrombosis on
the well-being of their patients.Acknowledgements
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Sample items1 venous thrombosis-quality of life
(VT-QOL) questionnaire.
During the past 4 weeks, to what extent did
your thrombosis problem limit you while doing the
following activities? (Please circle the number
corresponding to the right answer.)ot limited
t all
A little
limited
Moderately
limited
Very
limited
Impossible
to do so
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
1 The complete questionnaire can be obtained from I.M. van
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